Cargando…

Characterization of trans‐ and cis‐cleavage activity of the SARS coronavirus 3CL(pro) protease: basis for the in vitro screening of anti‐SARS drugs

Severe acute respiratory syndrome (SARS) has been globally reported. A novel coronavirus (CoV), SARS‐CoV, was identified as the etiological agent of the disease. SARS‐CoV 3C‐like protease (3CL(pro)) mediates the proteolytic processing of replicase polypeptides 1a and 1ab into functional proteins, pl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Cheng-Wen, Tsai, Chang-Hai, Tsai, Fuu-Jen, Chen, Pei-Jer, Lai, Chien-Chen, Wan, Lei, Chiu, Hua-Hao, Lin, Kuan-Hsun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2004
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127318/ https://www.ncbi.nlm.nih.gov/pubmed/15358553 http://dx.doi.org/10.1016/j.febslet.2004.08.017

Ejemplares similares

Binding interaction of SARS coronavirus 3CL(pro) protease with vacuolar‐H(+) ATPase G1 subunit
por: Lin, Cheng-Wen, et al.
Publicado: (2005)

Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV
por: Chang, Yu-Jen, et al.
Publicado: (2023)

Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease
por: Shao, Yi-Ming, et al.
Publicado: (2008)

Coronavirus 3CL(pro )proteinase cleavage sites: Possible relevance to SARS virus pathology
por: Kiemer, Lars, et al.
Publicado: (2004)

Study of Baicalin toward COVID-19 Treatment: In silico Target Analysis and in vitro Inhibitory Effects on SARS-CoV-2 Proteases
por: Lin, Chingju, et al.
Publicado: (2021)

Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds
por: Lin, Cheng-Wen, et al.
Publicado: (2005)

Inhibition of the SARS-CoV-2 3CL(pro) main protease by plant polyphenols
por: Bahun, Miha, et al.
Publicado: (2022)

Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022)

Profiling of Substrate Specificity of SARS-CoV 3CL(pro)
por: Chuck, Chi-Pang, et al.
Publicado: (2010)

Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL(PRO) and 3CL(PRO) proteases
por: Jade, Dhananjay, et al.
Publicado: (2021)

Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2
por: Zhao, Yao, et al.
Publicado: (2022)

In silico screening of potential compounds from begonia genus as 3CL protease (3Cl pro) SARS-CoV-2 inhibitors
por: Maulana, Saipul, et al.
Publicado: (2023)

Mechanism of the Maturation Process of SARS-CoV 3CL Protease
por: Hsu, Min-Feng, et al.
Publicado: (2005)

In silico analysis of echinocandins binding to the main proteases of coronaviruses PEDV (3CL(pro)) and SARS-CoV-2 (M(pro))
por: Vergoten, Gérard, et al.
Publicado: (2021)

Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors
por: Chen, Li-Rung, et al.
Publicado: (2005)

Formation, Characterization, and Bonding of cis- and trans-[PtCl(2){Te(CH(2))(6)}(2)], cis-trans-[Pt(3)Cl(6){Te(CH(2))(6)}(4)], and cis-trans-[Pt(4)Cl(8){Te(CH(2))(6)}(4)]: Experimental and DFT Study †
por: Rodewald, Marko, et al.
Publicado: (2023)

Inhibition of SARS-CoV 3CL protease by flavonoids
por: Jo, Seri, et al.
Publicado: (2019)

Evaluation of metal‐conjugated compounds as inhibitors of 3CL protease of SARS‐CoV
por: Hsu, John T.-A., et al.
Publicado: (2004)

Interaction of Cis- and Trans-RuCl (2)(DMSO)(4) With Human Serum Albumin
por: Trynda-Lemiesz, Lilianna, et al.
Publicado: (2000)

Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants
por: Tahir ul Qamar, Muhammad, et al.
Publicado: (2020)

Cascading cis-Cleavage on Transcript from trans-Acting siRNA-Producing Locus 3
por: Zhang, Changqing, et al.
Publicado: (2013)

Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
por: Iketani, Sho, et al.
Publicado: (2020)

Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
por: Iketani, Sho, et al.
Publicado: (2021)

Structural basis for extracellular cis and trans RPTPσ signal competition in synaptogenesis
por: Coles, Charlotte H., et al.
Publicado: (2014)

Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease
por: Liu, Yu-Chih, et al.
Publicado: (2005)

Exploration of chalcones as 3-chymotrypsin-like protease (3CL(pro)) inhibitors of SARS-CoV-2 using computational approaches
por: Lam, Thua-Phong, et al.
Publicado: (2022)

Insilico generation of novel ligands for the inhibition of SARS-CoV-2 main protease (3CL(pro)) using deep learning
por: Prabhakaran, Prejwal, et al.
Publicado: (2023)

Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib
por: Niesor, Eric J, et al.
Publicado: (2021)

Engineering a novel endopeptidase based on SARS 3CL(pro)
por: Kuo, Chih-Jung, et al.
Publicado: (2009)

CRISPR-Cas12a has both cis- and trans-cleavage activities on single-stranded DNA
por: Li, Shi-Yuan, et al.
Publicado: (2018)

Polyprotein cleavage mechanism of SARS CoV M(pro) and chemical modification of the octapeptide
por: Du, Qi-Shi, et al.
Publicado: (2004)

Molecular Basis for Paradoxical Activities of Polymorphonuclear Neutrophils in Inflammation/Anti-Inflammation, Bactericide/Autoimmunity, Pro-Cancer/Anticancer, and Antiviral Infection/SARS-CoV-II-Induced Immunothrombotic Dysregulation
por: Wu, Tsai-Hung, et al.
Publicado: (2022)

Structural Characterization of Cis– and Trans–Pt(NH(3))(2)Cl(2) Conjugations with Chitosan Nanoparticles
por: Chanphai, Penparapa, et al.
Publicado: (2022)

Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity
por: Du, Lanying, et al.
Publicado: (2007)

DFT and MD simulation investigation of favipiravir as an emerging antiviral option against viral protease (3CL(pro)) of SARS-CoV-2
por: Yadav, Pooja, et al.
Publicado: (2021)

Assessment of activity of chalcone compounds as inhibitors of 3-chymotrypsin like protease (3CL(Pro)) of SARS-CoV-2: in silico study
por: Mathpal, Shalini, et al.
Publicado: (2022)

Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CL(Pro)) Activity
por: Guijarro-Real, Carla, et al.
Publicado: (2021)

Engineering of DNA Structures Attached to Magnetic Particles for Effective Trans- and Cis-Cleavage in Cas12-Based Biosensors
por: Ivanov, Aleksandr V., et al.
Publicado: (2023)

Computational View toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease
por: Qiao, Zhen, et al.
Publicado: (2020)

Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
por: Iketani, Sho, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a28o1kshrqicspo0bigsj7h3bf